Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib
Massimo Breccia MD, Department of Human Biotechnology and Hematology, Via Benevento 6, 00161 Roma, Italy
Tel: 003 906 857 951
Fax: 003 906 442 41984
e-mail: [email protected]
Abstract
Abstract: Imatinib related non-haematological side-effects are reported in <10% of chronic myeloid leukaemia patients and include oedema, weight gain, nausea, vomiting and muscle cramps. Cutaneous reactions are well-recognized events occurring mostly in patients treated at doses of 600 mg/d and higher, either in stable or progressive disease. We report on our experience relating to dermatological toxicities in imatinib treated CML patients showing a spectrum of skin reactions ranging from rashes to cutaneous carcinoma.
